The DREAM trial – Authors' reply
The DOI matches its Crossref record.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have shown that the rate of conversion of impaired glucose tolerance to type 2 diabetes mellitus is reduced with lifestyle modification 7 ; the use of metformin, 7 thiazolidinediones, [8][9][10][11] or acarbose 12 ; and bariatric surgery.13”
From Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance (2011) · cites this paper as [9]
In the citing paper
“In one study, 9 the use of rosiglitazone decreased the risk of diabetes in adults with impaired glucose tolerance by 62%; given concerns about cardiovascular safety, 14 however, the Food and Drug Administration has restricted the use of rosig litazone therapy to patients in whom glycemic control cannot be achieved with other medications and who cannot take pioglitazone.”
From Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance (2011) · cites this paper as [9]
In the citing paper
“Given the availability of effective interventions for delaying or preventing the onset of type 2 diabetes and the increasing burden of the condition worldwide, earlier identification of individuals at risk is particularly important3-6.”
From Metabolite profiles and the risk of developing diabetes (2011) · cites this paper as [6]
Citations
Cites
Still being checked.
Cited by
Metabolite profiles and the risk of developing diabetes
Wang, T. J., Larson, M. G., Vasan, R. S., Cheng, S., Rhee, E. P., McCabe, E., Lewis, G. D., Fox, C. S., Jacques, P. F., Fernandez, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2307 · Cited by 3,143
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010949 · Cited by 766
Gestational Diabetes Mellitus: Risks and Management during and after Pregnancy
Buchanan, T. A., Xiang, A. H., & Page, K. A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.96 · Cited by 718
Lago, R. M., Singh, P. P., & Nesto, R. W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61514-1 · Cited by 710
Metadata
- Authors
- Gerstein, H. C., Yusuf, S., & Bosch, J.
- Affiliations
- Population Health Research Institute (CA)
- Corresponding author
- Gerstein, Hertzel C
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2006-12
- Volume
- 368
- Issue
- 9552
- Pages
- 2050-2051
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2009383056
- Semantic Scholar
- 03f07b0c35fc1b335b15eb5d41f8c9eece84cf4f
- Cited by
- 253
- References
- 0
- Citations by year
- 2024: 1 · 2023: 1 · 2022: 2 · 2021: 1 · 2020: 2 · 2018: 4 · 2017: 7 · 2016: 8 · 2015: 12 · 2014: 10 · 2013: 18 · 2012: 17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- DREAM trial, diabetes prevention, cardiovascular outcomes, trial power, statins, high-risk patients
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The DREAM trial – Authors' reply. https://app.cochat.ai/papers/10.1016/s0140-6736(06)69829-2
- The paper
- Gerstein, H. C., Yusuf, S., & Bosch, J. (2006). The DREAM trial – Authors' reply. The Lancet. https://doi.org/10.1016/s0140-6736(06)69829-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.